U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/037,480	
			LOSURE	Filing Date	January 4, 2002	
				First Named Inventor	Gregor Cevc	
			essary)	Art Unit	1797	
		Examiner Name	Ana M. Fortuna			
Sheet	1	Of	1	Attorney Docket Number	35946-703.301	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶ .
	1.	EP 0152379 A2 (in German with English abstract)	02/11/1985	Muntwyler et al.		

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1				
	2.	ANOSOV, et al. Electrical capacitance of hydrogenated egg lecithin bilayer lipid membranes in the lipid crystal to gel phase transition. Biofizika. 2003; 48(2): 240-245. (English Abstract)			
	3.	BURNHAM et al. The effectiveness of topical diclofenac for lateral epicondylitis. Clin J Sport Med. 1998; 8(2):78-81.			
	4.	CEVC et al. Ultradeformable lipid vesicles can penetrate the skin and other semi- permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochimica et Biophysica Acta. 2002; 1564:21-30.			
	5.	ERJAVEC, et al. In Vivo Study of Liposomes as Drug Carriers to Oral Mucosa using EPR Oximetry. Int. J. Pharmaceut. 2006; 307:1-8.			
	6.	FRISKEN, et al. Studies of vesicle extrusion. Langmuir. 2000; 16:928-933.			
	7.	HUNTER, et al. Effect of extrusion pressure and lipid properties on the size and polydispersity of lipid vesicles. Biophys J. 1998; 74:2996-3002.			
	8.	SAUNDERS et al. A novel skin penetration enhancer: evaluation by membrane diffusion and confocal microscopy. J Pharm Pharmaceut Sci. 1999; 2(3):99-107.			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ¹See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.